Biogen chops expenses in Q2, raises 2022 profit forecast

Cost cutting helped Biogen beat second-quarter expectations soundly even as revenue slid and sales of the drugmaker’s controversial Alzheimer’s treatment collapsed. Aduhelm, a drug once expected to generate billions in annual sales, brought in only $100,000 in the quarter....